Vimarsana
Biggest News Aggregation in the World

A 239 Ve News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from A 239 Ve. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In A 239 Ve Today - Breaking & Trending Today

Celcuity Inc.: Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress - Vimarsana News

Celcuity Inc.: Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Published: May 12, 2023

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian

Source: finanznachrichten.de
Related Topics:
San AntonioUnited StatesVicky HahneRobert UhlBrian SullivanIgor GorbatchevskyBreast Cancer Congress See TableBreast Cancer Annual CongressEuropean Society For Medical OncologyExchange Commission OnCelcuity Inc ViewCelcuity IncMedical OncologyEscalation ArmExpansion ArmSan Antonio Breast Cancer SymposiumChief Medical OfficerStudy DesignCancer CongressMeasurable DiseaseFree SurvivalFull Analysis SetBreakthrough TherapyRisk FactorsAnnual Report
Novartis Pharma AG: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients - Vimarsana News

Novartis Pharma AG: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

Published: April 26, 2023

Data at EBMT show primary endpoint met - estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline

Source: finanznachrichten.de
Related Topics:
South KoreaFrance GeneralUnited StatesSatoshi SugimotoJulie MasowGiuseppe MoscatiSamir ShahDavid SoergelAnn HematolMary CarmichaelAntonio RisitanoIptacopan MonotherapyMarlena AbdinoorMichael MeoNicole Zinsli SommIsabella ZinckRichard JarvisSloan SimpsonParag MahantiValue HealthMetabolism Development UnitGreater Paris University HospitalEuropean Medicines AgencyNovartis Institutes For Biomedical ResearchInterest Group
AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients - Vimarsana News

AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients

Published: December 11, 2022

WASHINGTON (dpa-AFX) - AbbVie (ABBV) said the exploratory analysis from Cohort 3 of the Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve

Source: finanznachrichten.de
Related Topics:
United StatesAmerican Society Of Hematology Annual Meeting ExpositionAmerican SocietyHematology Annual MeetingA 239 Ve